Georgia Medical Cannabis Expansion Passes House in Historic 138-21 Bipartisan Vote

What SB220 Changes for Georgia's Medical Cannabis Program

The amended bill represents the most sweeping update to Georgia's medical cannabis framework in over a decade.

Vaping Now Allowed for Patients 21 and Older

For the first time, Georgia medical cannabis patients would be able to vaporize cannabis products. Previously, the state only permitted low-THC oil, capsules, and tinctures.

The inclusion of vaporization is seen as a major step toward giving patients access to faster-acting relief, since inhaled cannabis typically takes effect within minutes compared to the 30-90 minutes required for oils and edibles.

THC Limits Restructured

The current law caps THC potency at 5% — one of the lowest in the nation for medical programs. Under SB220, that potency cap would be replaced with a possession limit of 12,000 milligrams of THC at any one time.

This shift gives patients access to higher-potency products while still capping the total amount they can hold. For context, 12,000mg of THC is roughly equivalent to about 40 standard vape cartridges or 1,200 standard edible doses.

New Qualifying Conditions Added

The bill adds lupus, severe arthritis, and severe insomnia to the list of conditions eligible for a Georgia medical cannabis card.

It also removes restrictive language that limited many existing conditions to "severe" or "end-of-life" cases, potentially opening the program to thousands of additional patients.

Georgia's Cannabis Program Has Struggled With Access

Georgia legalized low-THC cannabis oil in 2015 through Haleigh's Hope Act, named after a young girl with severe epilepsy. But for years, the program existed largely on paper.

Patients had a legal right to possess the oil, but there was no legal way to buy it in the state until the first dispensaries finally opened in 2023 — eight years after legalization.

Low Enrollment and Ineffective Products

Even after dispensaries began operating, patient enrollment remained low. The strict 5% THC cap meant that many patients found the available products ineffective for managing chronic pain, PTSD, and other serious conditions.

By early 2026, Georgia's medical cannabis program served a fraction of the patients that neighboring states like Florida and Alabama have enrolled.

The Bill's Legislative Journey

SB220's sponsor, Newnan Republican Senator Matt Brass, has argued that the program needs modernization to actually serve the patients it was designed to help.

The bill originally passed the Georgia Senate in March 2025 on a 39-17 vote but ran out of time in the House before the session adjourned. Thanks to Georgia's two-year legislative sessions, it carried over into 2026.

The Bipartisan Coalition Behind the Bill

The 138-21 House vote is remarkable in a state where cannabis reform has historically faced stiff opposition from conservative lawmakers. The lopsided tally suggests that medical cannabis has crossed a partisan threshold in Georgia, with overwhelming support from both Republicans and Democrats.

What Shifted the Political Landscape

Advocates credit several factors for the shift:

• Patient testimonials have been a powerful force in the Georgia legislature, particularly stories from veterans, cancer patients, and parents of children with epilepsy
• The economic argument has gained traction — neighboring states with robust medical cannabis programs generate hundreds of millions in tax revenue and have created thousands of jobs
• National momentum has played a role, with President Trump's executive order directing the rescheduling of cannabis from Schedule I to Schedule III and nearly 40 states now operating some form of legal cannabis program

What Happens Next

The bill's fate now rests with the Georgia Senate, which must vote to concur with the House amendments before the April 4 deadline. Since the Senate already passed an earlier version of SB220 with a strong 39-17 vote, concurrence is considered likely — though any disagreements over the House amendments could complicate the timeline.

Implementation Timeline

If signed into law, SB220 would not take effect immediately. The Georgia Access to Medical Cannabis Commission would need to:

• Update its regulations
• Approve new product categories
• Establish testing standards for vaporizable products

Industry observers expect it could take six to twelve months before patients see new products on dispensary shelves.

Impact on Georgia's Licensed Companies

Georgia's six licensed cannabis companies — which have struggled with low patient counts and restrictive product limits — stand to benefit significantly. Higher THC allowances and the addition of vaping products could attract a wave of new patients and boost revenue in a market that has underperformed expectations.

What This Means for the Southeast

Georgia's move comes at a pivotal time for cannabis in the Southeast:

• Alabama is preparing to open its first medical cannabis dispensaries in 2026, nearly five years after legalization
• Florida's recreational legalization push was blocked from the 2026 ballot by the state Supreme Court
• Tennessee is debating its "Pot for Potholes Act," which would legalize adult-use cannabis and dedicate tax revenue to road repair

If SB220 becomes law, Georgia would join a growing cohort of Southern states that are cautiously expanding cannabis access through medical programs — even as full recreational legalization remains politically out of reach in the region.

For Georgia's estimated 400,000 patients who could benefit from medical cannabis, the bill represents something simpler: the possibility of relief that actually works.